Retatrutide and Tirzepatide are both incretin-based therapies, with studies suggesting their primary utility in metabolic disease management, particularly for weight loss and improving cardiometabolic health. Retatrutide, a triple agonist, has shown significant weight loss and improvements in glycemic and lipid parameters in meta-analyses, indicating a broad therapeutic potential for obesity and related metabolic disorders. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has also demonstrated substantial weight loss in non-diabetic adults and broad health benefits extending to cardiovascular, renal, and liver protection, as supported by meta-analyses.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Drug class | glp 1 agonist, gip agonist, glucagon agonist | glp 1 agonist, gip agonist |
| Studies in corpus | 153 | 722 |
| Highest evidence tier | meta analysis | — |
| Evidence tier mix | review · 49 preclinical animal · 11 meta analysis · 25 other · 21 rct · 23 in vitro · 1 | n/a |
| Studies with explicit sample size | 2 | 0 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Retatrutide and Tirzepatide batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 10342 Retatrutide batches across 2400 manufacturers, 99.65% avg purity.
We tested 7723 Tirzepatide batches across 1544 manufacturers, 99.69% avg purity.
We hold deeper lab coverage on Retatrutide (10342 batches tested). Tirzepatide edges ahead on average measured purity (99.65% vs 99.69%) — a narrow gap; weigh it against failed-batch and underdose counts above.
No direct head-to-head trials in our corpus. Indirect comparison only. Retatrutide is characterized as a triple incretin agonist, while Tirzepatide is a dual GIP/GLP-1 receptor agonist. Both peptides are noted for their efficacy in metabolic disorders, with reviews highlighting their potential to improve outcomes for individuals managing Type 2 Diabetes, obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD). While both show promise in cardiovascular benefits, specific studies on Retatrutide emphasize its impact on kidney transplant patients, showing improvements in metabolic parameters and a reduction in new-onset post-transplant diabetes mellitus. Tirzepatide's broader health benefits are suggested to extend to multi-organ protection, including cardiovascular disease, chronic kidney disease, and non-alcoholic fatty liver disease, potentially independent of its metabolic effects. The corpus includes a higher number of studies on Tirzepatide (536) compared to Retatrutide (140), potentially indicating a more extensive body of research for Tirzepatide at this time.
Looking for vendor-level purity, endotoxin, and HPLC data on Retatrutide or Tirzepatide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.